ArticlePloS one2024

Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.

Tarun Mehra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.